⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LBRX News
LB Pharmaceuticals Inc Common Stock
Lumen Bio Reports Positive Phase 2 Results from the RePreve Clinical Trial (LMN-201 for C. difficile Infection)
prnewswire.com
LBRX
LB Pharmaceuticals to Participate in Upcoming Investor Events
globenewswire.com
LBRX
LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress
globenewswire.com
LBRX
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
LBRX
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
globenewswire.com
LBRX
Form 8-K
sec.gov
LBRX
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
globenewswire.com
LBRX
LB Pharmaceuticals to Participate in Upcoming September Investor Events
globenewswire.com
LBRX
Form 8-K
sec.gov
LBRX
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
globenewswire.com
LBRX